Ji Wu, Jian Li, Bo Huang, Sunbin Dong, Luyang Wu, Xiping Shen, Zhigang Zheng
{"title":"ConvXGB:利用多参数MRI图像预测早期宫颈癌术后复发风险的新型深度学习模型。","authors":"Ji Wu, Jian Li, Bo Huang, Sunbin Dong, Luyang Wu, Xiping Shen, Zhigang Zheng","doi":"10.1016/j.tranon.2025.102281","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Accurate estimation of recurrence risk for cervical cancer plays a pivot role in making individualized treatment plans. We aimed to develop and externally validate an end-to-end deep learning model for predicting recurrence risk in cervical cancer patients following surgery by using multiparametric MRI images.</p><p><strong>Methods: </strong>The clinicopathologic data and multiparametric MRI images of 406 cervical cancer patients from three institutions were collected. We designed a novel deep learning model called \"ConvXGB\" for predicting recurrence risk by combining the convolutional neural network (CNN) and eXtreme Gradient Boost (XGBoost). The predictive performance of the ConvXGB model was evaluated using time-dependent area under curve (AUC), compared with the deep learning radio-clinical model, clinical model, conventional radiomics nomogram and an existing histology-specific tool. The potential of the ConvXGB model in predicting the recurrence-free survival (RFS) and overall survival (OS) was assessed.</p><p><strong>Results: </strong>The ConvXGB model outperformed other models in predicting recurrence risk, with AUCs for 1 and 3 year-RFS of 0.872(95% CI, 0.857-0.906) and 0.882(95% CI, 0.860-0.904) respectively in the test cohort. This model showed better discrimination, calibration and clinical utility. Grad-CAM analysis was adopted to help clinicians better understand the predictive results. Moreover, Kaplan-Meier survival analysis revealed that patients who were stratified into high-risk group by the ConvXGB model were significantly susceptible to higher cumulative recurrence risk rates and worse outcome.</p><p><strong>Conclusion: </strong>The ConvXGB model allowed for predicting postoperative recurrence risk in cervical cancer patients and for stratifying the risk of RFS and OS.</p>","PeriodicalId":23244,"journal":{"name":"Translational Oncology","volume":"52 ","pages":"102281"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773201/pdf/","citationCount":"0","resultStr":"{\"title\":\"ConvXGB: A novel deep learning model to predict recurrence risk of early-stage cervical cancer following surgery using multiparametric MRI images.\",\"authors\":\"Ji Wu, Jian Li, Bo Huang, Sunbin Dong, Luyang Wu, Xiping Shen, Zhigang Zheng\",\"doi\":\"10.1016/j.tranon.2025.102281\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Accurate estimation of recurrence risk for cervical cancer plays a pivot role in making individualized treatment plans. We aimed to develop and externally validate an end-to-end deep learning model for predicting recurrence risk in cervical cancer patients following surgery by using multiparametric MRI images.</p><p><strong>Methods: </strong>The clinicopathologic data and multiparametric MRI images of 406 cervical cancer patients from three institutions were collected. We designed a novel deep learning model called \\\"ConvXGB\\\" for predicting recurrence risk by combining the convolutional neural network (CNN) and eXtreme Gradient Boost (XGBoost). The predictive performance of the ConvXGB model was evaluated using time-dependent area under curve (AUC), compared with the deep learning radio-clinical model, clinical model, conventional radiomics nomogram and an existing histology-specific tool. The potential of the ConvXGB model in predicting the recurrence-free survival (RFS) and overall survival (OS) was assessed.</p><p><strong>Results: </strong>The ConvXGB model outperformed other models in predicting recurrence risk, with AUCs for 1 and 3 year-RFS of 0.872(95% CI, 0.857-0.906) and 0.882(95% CI, 0.860-0.904) respectively in the test cohort. This model showed better discrimination, calibration and clinical utility. Grad-CAM analysis was adopted to help clinicians better understand the predictive results. Moreover, Kaplan-Meier survival analysis revealed that patients who were stratified into high-risk group by the ConvXGB model were significantly susceptible to higher cumulative recurrence risk rates and worse outcome.</p><p><strong>Conclusion: </strong>The ConvXGB model allowed for predicting postoperative recurrence risk in cervical cancer patients and for stratifying the risk of RFS and OS.</p>\",\"PeriodicalId\":23244,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"52 \",\"pages\":\"102281\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773201/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tranon.2025.102281\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tranon.2025.102281","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
ConvXGB: A novel deep learning model to predict recurrence risk of early-stage cervical cancer following surgery using multiparametric MRI images.
Background: Accurate estimation of recurrence risk for cervical cancer plays a pivot role in making individualized treatment plans. We aimed to develop and externally validate an end-to-end deep learning model for predicting recurrence risk in cervical cancer patients following surgery by using multiparametric MRI images.
Methods: The clinicopathologic data and multiparametric MRI images of 406 cervical cancer patients from three institutions were collected. We designed a novel deep learning model called "ConvXGB" for predicting recurrence risk by combining the convolutional neural network (CNN) and eXtreme Gradient Boost (XGBoost). The predictive performance of the ConvXGB model was evaluated using time-dependent area under curve (AUC), compared with the deep learning radio-clinical model, clinical model, conventional radiomics nomogram and an existing histology-specific tool. The potential of the ConvXGB model in predicting the recurrence-free survival (RFS) and overall survival (OS) was assessed.
Results: The ConvXGB model outperformed other models in predicting recurrence risk, with AUCs for 1 and 3 year-RFS of 0.872(95% CI, 0.857-0.906) and 0.882(95% CI, 0.860-0.904) respectively in the test cohort. This model showed better discrimination, calibration and clinical utility. Grad-CAM analysis was adopted to help clinicians better understand the predictive results. Moreover, Kaplan-Meier survival analysis revealed that patients who were stratified into high-risk group by the ConvXGB model were significantly susceptible to higher cumulative recurrence risk rates and worse outcome.
Conclusion: The ConvXGB model allowed for predicting postoperative recurrence risk in cervical cancer patients and for stratifying the risk of RFS and OS.
期刊介绍:
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.